Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer

Next Previous
Trial Profile

Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maveropepimut-S (Primary) ; Cyclophosphamide
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AVALON
  • Sponsors IMV

Most Recent Events

  • 11 Sep 2023 Status changed from recruiting to discontinued.
  • 21 Aug 2023 This trial has been completed in France, according to European Clinical Trials Database record.
  • 01 May 2023 According to IMV media release, the company expects that it will have sufficient funds to complete its CCAA proceedings and potential restructuring. The company's Dartmouth, Nova Scotia headquarters and laboratories remain open in a limited capacity and its clinical trials, including this study will pause enrollment, pending the outcome of the review of strategic alternatives.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top